# The effect of Marinol (tetra-9-hydrocannabinol) on the frequency of TLESRs.

No registrations found.

**Ethical review** Positive opinion

**Status** Recruitment stopped

Health condition type -

**Study type** Interventional

## **Summary**

#### ID

NL-OMON21968

**Source** 

NTR

**Brief title** 

N/A

Intervention

#### **Outcome measures**

## **Primary outcome**

Frequency of transient lower esophageal sfincter relaxations (TLESRs) measured by esophageal manometry up to 3hours postprandially.

#### **Secondary outcome**

Rate of acid reflux episodes measured with pH-metry for 3 hours postprandially, basal lower esophageal sphincter pressure (LESp) measured by manometry.

# **Study description**

## **Background summary**

Remark randomization: Every subject is his own control.

## Study objective

Cannabinoid receptor (CB1) agonists, like marinol, lower the rate of TLESRs and can be useful in the treatment of gastroesophageal reflux disease (GERD).

## Study design

N/A

#### Intervention

Twice a 4 hours esophageal manometry and pH-metry (transnasally).

Single dose of 10mg marinol (delta-9-hydrocannabinol, THC) and a single dose of placebo.

## **Contacts**

#### **Public**

Academic Medical Center (AMC), Department of Gastroenterology, C2-328,

P.O. Box 22660

G.E.E. Boeckxstaens

Meibergdreef 9

Amsterdam 1100 DD

The Netherlands

+31 (0)20 5667375

#### **Scientific**

Academic Medical Center (AMC), Department of Gastroenterology, C2-328,

P.O. Box 22660

G.E.E. Boeckxstaens

Meibergdreef 9

Amsterdam 1100 DD

The Netherlands

+31 (0)20 5667375

# **Eligibility criteria**

## Inclusion criteria

- 1. Man,
- 2. 18-55 years,
- 3. 65-100kg,
- 4. bmi 19-30 kg/m2,
- 5. normal fysical and laboratorial findings at start of study.

## **Exclusion criteria**

- 1. Clinical relevant illness two weeks prior to start of study;
- 2. systemic illness which influence esophageal motility;
- 3. use of drugs that influence gastrointestinal motility;
- 4. drug abuse,
- 5. mania, depression, schizofrenia or another mental illness;
- 6. cardiac complaints as hypo-. hypertension, syncope, tachycardia;
- 7. cannabis allergy,
- 8. sesame oil allergy or another severe allergy.

# Study design

## **Design**

Study type: Interventional

Intervention model: Crossover

Allocation: Randomized controlled trial

Masking: Double blinded (masking used)

3 - The effect of Marinol (tetra-9-hydrocannabinol) on the frequency of TLESRs. 7-05-2025

Control: Placebo

## Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 03-05-2004

Enrollment: 18

Type: Actual

## **Ethics review**

Positive opinion

Date: 31-05-2005

Application type: First submission

# **Study registrations**

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

RegisterIDNTR-newNL30NTR-oldNTR52

Other : MEC 04/084 ISRCTN ISRCTN34437109

# **Study results**

**Summary results** 

N/A